Bipolar I Disorder With Depressive Episodes Therapeutics
1. Latuda patent expiration
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia; Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treat...
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532372 | SUNOVION | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| USRE45573 | SUNOVION | Process for producing imide compound |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5532372 | SUNOVION | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| US9815827 | SUNOVION | Agent for treatment of schizophrenia |
Feb, 2024
(2 years ago) | |
|
US5532372 (Pediatric) | SUNOVION | Imide derivatives, and their production and use |
Jan, 2019
(7 years ago) | |
| US9555027 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US9827242 | SUNOVION | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
| US9174975 | SUNOVION | Remedy for integration dysfunction syndrome |
Feb, 2024
(2 years ago) | |
| US9259423 | SUNOVION | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
|
US9174975 (Pediatric) | SUNOVION | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 6 months ago) | |
| US8729085 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US9907794 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US8883794 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
|
US8729085 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US8883794 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US9907794 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US9259423 (Pediatric) | SUNOVION | Method of treatment for mental disorders |
Nov, 2031
(5 years from now) | |
|
USRE45573 (Pediatric) | SUNOVION | Process for producing imide compound |
Dec, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
